Royalty Pharma has signed a deal to pay Biogen $250m to support the development of its late-stage experimental lupus ...

Patients with CLE who have specific patient characteristics may have lower treatment response than patients who do not have these characteristics.

Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis.

In addition to glucocorticoids, medications that may increase the likelihood of experiencing disturbed sleep include the biologic belimumab and the antimalarial drug hydroxychloroquine.

particularly glucocorticoids Using antimalarials and immunosuppressives both to control disease in the long term and avoid 'spare' glucocorticoids Belimumab Minor arthritis, mild pleurisy NSAIDs ...

Saphnelo will compete in the market most closely with GlaxoSmithKline's BLyS inhibitor Benlysta (belimumab), which has been available in the EU to treat SLE since 2011 and recorded worldwide sales ...

Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company targets the billion-dollar lupus market for its CD20-targeting drug Gazyva ...

Int J Clin Rheumatol. 2010;5(4):407-413.

Objectives To identify factors that predict response to belimumab treatment in the phase 3 BLISS trials of autoantibody-positive systemic lupus erythematosus (SLE) and further analyse clinical ...

The factors contributing to the treatment efficacy of belimumab in patients with systemic lupus erythematosus (SLE) in the maintenance phase are unknown. Here, we collected blood samples from patients ...